Dr. Ira Spector is an experienced drug developer, with over 25 years of experience in drug and medical device development. He has helped develop 33 approved drugs and 12 medical devices, including Enbrel, Effexor, Protonix, Prevenar-13, and Mylotarg. He was VP of Clinical Operations and Vice-Chief of Development at Wyeth; and was responsible for managing one of the world’s largest adult vaccine trials, in Community Acquired Pneumonia in adults, with 85,517 subjects, that led to the approval of Prevenar-13; and one of World’s largest Alzheimer’s disease trials, with 4,000 subjects; and one of the largest clinical programs in breast cancer, with over 4,000 subjects. At Allergan, he helped develop Ozurdex for Diabetic Macular Edema and Retinal Venous Occlusion, Botox for Overactive Bladder, Botox for Chronic Migraine, Juvederm XL and Botox for Cerebral Palsy. Dr. Spector is a co-founder of SFA Therapeutics, a startup company focused on a new advance in treating inflammatory diseases.